<DOC>
	<DOCNO>NCT00490646</DOCNO>
	<brief_summary>The purpose randomize , Phase 2 open-label study assess response rate participant Human Epidermal Growth Factor Receptor 2 ( Her2+ ) locally advanced and/or metastatic breast cancer ( previously treat chemotherapy trastuzumab ) treatment ixabepilone plus trastuzumab and/or docetaxel plus trastuzumab .</brief_summary>
	<brief_title>A Phase II Combination Trastuzumab Ixabepilone Versus Trastuzumab Docetaxel Patients With Advanced and/or Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Locally advanced metastatic HER2+ breast cancer previously treat chemotherapy trastuzumab . Subjects receive prior ( neo ) adjuvant chemotherapy trastuzumab eligible except relapse within 12 month last dose taxane trastuzumab give ( neo ) adjuvant therapy . Measurable disease Left Ventricular Ejection Fraction ( LVEF ) â‰¥50 % Prior chemotherapy trastuzumab metastatic breast cancer ( MBC ) Relapse within 1 year ( neo ) adjuvant taxane trastuzumab Neuropathy &gt; Grade 1 Significant cardiovascular disease Any brain metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Locally advanced and/or metastatic breast cancer</keyword>
</DOC>